Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
Status:
Completed
Trial end date:
2012-12-08
Target enrollment:
Participant gender:
Summary
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed
prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune
response in children receiving primary vaccination with GlaxoSmithKline (GSK) Biologicals'
10-valent pneumococcal conjugate vaccine, co-administered with DTPa-combined vaccines, at 3,
4 and 5 months of age.
In addition, this study will further evaluate the impact of prophylactic administration of
paracetamol following primary vaccination with immediate or delayed administration or when
given in an immediate manner at the time of the booster dose.